Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04488913 · ClinicalTrials.gov registry record · NA
Rapid Acute Coronary Syndrome Exclusion Using High-sensitivity I Troponin
A NA study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- NA
- Development phase
- 32,609
- Enrollment target
NCT04488913: Completed NA study, sponsored by Henry Ford Health System.
NCT04488913 is a NA study that has completed, run by Henry Ford Health System. The registered enrollment target is 32,609 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (2224% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04488913, a NA study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 32,609 participants
- Enrollment target
Study Summary
As part of the planned implementation of a new clinical pathway using hs-cTnI, the investigators will measure patient outcomes and clinical processes in a real-world scenario throughout an integrated health system across 9 emergency departments (ED).
Primary Outcome
Proportion of patients with safe discharges home from the ED, defined as being without death or acute myocardial infarction within 30-days
Interventions
- OTHER Standard of Care
- OTHER RACE-IT Pathway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32,609 participants |
| Start Date | 2020-07-29 |
| Est. Completion | 2022-03-03 |
| Phase | NA |
What the finished NCT04488913 record still lists
NCT04488913 is an interventional study that assigns participants to a tested intervention. Its 32,609 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (2224% higher).
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT04488913 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04488913 about?
NCT04488913 is a clinical study titled "Rapid Acute Coronary Syndrome Exclusion Using High-sensitivity I Troponin". As part of the planned implementation of a new clinical pathway using hs-cTnI, the investigators will measure patient outcomes and clinical processes in a real-world scenario throughout an integrated health system across 9 emergency departments (ED).
What is the current status of trial NCT04488913?
This trial is currently completed. It is a NA study. The enrollment target is 32,609 participants. The study started on 2020-07-29. Estimated completion is 2022-03-03.
What interventions are being tested in trial NCT04488913?
The interventions under investigation include: Standard of Care (OTHER), RACE-IT Pathway (OTHER).
Who is sponsoring clinical trial NCT04488913?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04488913's enrollment target sits among peer trials
32,609 8th of 2000 higher than 1,993 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04477928 · 33,000 participants
General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery
- NCT06145724 · 33,183 participants · NA
EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 1)
- NCT07282665 · 32,000 participants · Phase 3
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
- NCT03720613 · 34,532 participants
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI